A Live, Attenuated<i>Bordetella pertussis</i>Vaccine Provides Long-Term Protection against Virulent Challenge in a Murine Model

Skerry, Ciaran; Mahon, Bernard P.

doi:10.1128/cvi.00371-10

Cited by 44 publications

(38 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unlike most classical adjuvants, PTX is able to concomitantly enhance Th1 and Th2 type CD4 + T cells [127,128] through costimulation via CD80 ⁄ CD86 molecules [125]. In addition, PTX used as an adjuvant is able to promote Th17 differentiation through IL-6 induction [129,130], which is in accordance with studies showing that B. pertussis infection induces a mixed Th1 ⁄ Th17 immune response [131,132]. When used as an adjuvant for experimental autoimmune encephalomyelitis, PTX also reduces the number and function of regulatory CD4 + T cells [133,134].…”

Section: Ptx Modulates Adaptive Immune Responsessupporting

confidence: 77%

The ins and outs of pertussis toxin

2011

View full text Add to dashboard Cite

Pertussis toxin, produced and secreted by the whooping cough agent Bordetella pertussis, is one of the most complex soluble bacterial proteins. It is actively secreted through the B. pertussis cell envelope by the Ptl secretion system, a member of the widespread type IV secretion systems. The toxin is composed of five subunits (named S1 to S5 according to their decreasing molecular weights) arranged in an A-B structure. The A protomer is composed of the enzymatically active S1 subunit, which catalyzes ADP-ribosylation of the a subunit of trimeric G proteins, thereby disturbing the metabolic functions of the target cells, leading to a variety of biological activities. The B oligomer is composed of 1S2:1S3:2S4:1S5 and is responsible for binding of the toxin to the target cell receptors and for intracellular trafficking via receptor-mediated endocytosis and retrograde transport. The toxin is one of the most important virulence factors of B. pertussis and is a component of all current vaccines against whooping cough.

show abstract

Section: Ptx Modulates Adaptive Immune Responsessupporting

confidence: 77%

The ins and outs of pertussis toxin

2011

View full text Add to dashboard Cite

show abstract

“…B pertussis, a gram-negative aerobic, pleomorphic coccobacilli, is known to cause whooping cough, which is a respiratory tract infection characterized by paroxysmal cough. [6][7][8][9] B pertussis is transmitted by large droplets produced during coughing, sneezing, or talking. These droplets generally travel fewer than 3 feet and can be deposited on mucosal surfaces of susceptible individuals.…”

Section: Discussionmentioning

confidence: 99%

Bordetella pertussis Infection in Patients with Cancer

Yacoub

Nanjappa²,

Janz³

et al. 2016

Cancer Control

View full text Add to dashboard Cite

We illustrate 2 cases of pneumonia associated with Bordetella pertussis infection in 72-year-old and 61-year-old patients with cancer receiving myelosuppressive therapy after hematopoietic stem cell transplantation. Bacterial infections are a significant cause of morbidity and mortality in patients with cancer, and those receiving hematopoietic stem cell transplant, solid organ transplant, or myelosuppressive therapy are at increased risk. The infection was detected and the 2 patients had good outcomes following azithromycin treatment. Pertussis, also known as whooping cough, is a contagious respiratory illness that has become a public health challenge due to decreased immunity of the pertussis vaccine. Therefore, it is critical to recognize pertussis early in the course of the disease.

show abstract

“…In preclinical mouse studies, BPZE1 induced long‐lasting protection (Feunou et al ., ; Skerry & Mahon, ). For up to at least 1 year, a single nasal administration of BPZE1 to adult or infant mice provided total protection against nasal challenge with virulent B. pertussis , whereas immunity induced by two administrations of Pa vaccine started to wane at 6 months after the last immunization.…”

Section: Novel Pertussis Vaccinesmentioning

confidence: 99%

New pertussis vaccination approaches: en route to protect newborns?

Locht

Mielcarek

2012

FEMS Immunol Med Microbiol

View full text Add to dashboard Cite

Pertussis or whooping cough is a life-threatening childhood disease, particularly severe during the first months of life, although adolescent and adult pertussis is increasingly more noted. General vaccination has tremendously reduced its incidence but has failed to bring it completely under control. In fact, it remains one of the most poorly controlled vaccine-preventable diseases in the world. New vaccination strategies are thus being explored. These include vaccination of pregnant mothers to transmit protective antibodies to the offspring, a cocooning strategy to prevent the transmission of the disease from family members to the newborn and neonatal vaccination. All have their inherent limitations, and improved vaccines are urgently needed. Two types of pertussis vaccines are currently available, whole-cell, first-generation and second-generation, acellular vaccines, with an improved safety profile. Attempts have been made to discover additional protective antigens to the 1-5 currently included in the acellular vaccines or to include new adjuvants. Recently, a live attenuated nasal Bordetella pertussis vaccine has been developed and undergone first-in-man clinical trials. However, as promising as it may be, in order to protect infants against severe disease, a single approach may not be sufficient, and multiple strategies applied in a concerted fashion may ultimately be required.

show abstract

A Live, AttenuatedBordetella pertussisVaccine Provides Long-Term Protection against Virulent Challenge in a Murine Model

Cited by 44 publications

References 45 publications

The ins and outs of pertussis toxin

The ins and outs of pertussis toxin

Bordetella pertussis Infection in Patients with Cancer

New pertussis vaccination approaches: en route to protect newborns?

Contact Info

Product

Resources

About